Beam Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Stock-Based Compensation Growth & History (BEAM)
Beam Therapeutics's stock-based compensation was $94.2M for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $94.2M | −$26.4M | −21.89% |
| 2024 | 2024-12-31 | $120.7M | $22.0M | +22.32% |
| 2023 | 2023-12-31 | $98.6M | $14.3M | +16.99% |
| 2022 | 2022-12-31 | $84.3M | $40.8M | +93.53% |
| 2021 | 2021-12-31 | $43.6M | $28.2M | +183.29% |
| 2020 | 2020-12-31 | $15.4M | $8.4M | +118.84% |
| 2019 | 2019-12-31 | $7.0M | — | — |
Beam Therapeutics quarterly stock-based compensation
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19.3M | −$5.1M | −20.88% |
| Q1 2026 | 2026-03-31 | $19.0M | −$7.6M | −28.63% |
| Q4 2025 | 2025-12-31 | $20.4M | −$9.8M | −32.33% |
| Q3 2025 | 2025-09-30 | $22.7M | −$6.8M | −23.05% |
| Q2 2025 | 2025-06-30 | $24.4M | −$7.2M | −22.90% |
| Q1 2025 | 2025-03-31 | $26.7M | −$2.6M | −8.88% |
| Q4 2024 | 2024-12-31 | $30.2M | $7.6M | +33.61% |
| Q3 2024 | 2024-09-30 | $29.6M | $3.7M | +14.41% |
| Q2 2024 | 2024-06-30 | $31.6M | $5.3M | +20.27% |
| Q1 2024 | 2024-03-31 | $29.3M | $5.4M | +22.43% |
| Q4 2023 | 2023-12-31 | $22.6M | $118,000 | +0.52% |
| Q3 2023 | 2023-09-30 | $25.8M | $3.6M | +16.33% |
| Q2 2023 | 2023-06-30 | $26.3M | $4.7M | +21.78% |
| Q1 2023 | 2023-03-31 | $23.9M | $5.9M | +32.61% |
| Q4 2022 | 2022-12-31 | $22.5M | $7.0M | +45.14% |
| Q3 2022 | 2022-09-30 | $22.2M | $9.2M | +71.26% |
| Q2 2022 | 2022-06-30 | $21.6M | $11.1M | +106.45% |
| Q1 2022 | 2022-03-31 | $18.0M | $13.4M | +288.02% |
| Q4 2021 | 2021-12-31 | $15.5M | $8.7M | +127.74% |
| Q3 2021 | 2021-09-30 | $13.0M | $10.0M | +330.54% |
| Q2 2021 | 2021-06-30 | $10.5M | $7.7M | +277.46% |
| Q1 2021 | 2021-03-31 | $4.6M | $1.9M | +66.48% |
| Q4 2020 | 2020-12-31 | $6.8M | $4.8M | +230.92% |
| Q3 2020 | 2020-09-30 | $3.0M | $983,000 | +48.45% |
| Q2 2020 | 2020-06-30 | $2.8M | $696,000 | +33.57% |
| Q1 2020 | 2020-03-31 | $2.8M | $1.9M | +221.29% |
| Q4 2019 | 2019-12-31 | $2.1M | — | — |
| Q3 2019 | 2019-09-30 | $2.0M | — | — |
| Q2 2019 | 2019-06-30 | $2.1M | — | — |
| Q1 2019 | 2019-03-31 | $869,000 | — | — |
Beam Therapeutics stock-based compensation trends
Over the last five fiscal years, Beam Therapeutics's stock-based compensation increased from $15.4M to $94.2M, a change of $78.9M. The latest reported quarter, Q2 2026, shows $19.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...